On Tuesday, mayhem in oil markets led to the crashing of Indian benchmark indices as Sensex plunged by 3.20 per cent which is 1,011.29 points to the level of 30,636.71 while, Nifty dipped by 3.03 per cent which is 280.40 points to be at the level of 8,981.45. In Sensex, 27 out of 30 stocks closed in red and only three stocks ended Tuesday market stir in green. Volatility index-India VIX jumped by more than four per cent to 45.34 level. 

Indian multinational information technology service & consulting company, Tata Consultancy Services (TCS) and American multi-level marketing company-Amway, have entered into a strategic partnership to transform latter’s global technology operations.

Tuesday morning was shocking as US crude oil i.e. WTI Crude price had fallen below zero. It isn’t the first time in 2020 for crude prices to plummet by a high percentage. However, post-noon, the WTI crude price showed a mere recovery by trading above zero to USD 0.10 per barrel.

On Tuesday, the shares of Aurobindo Pharma surged by more than 15 per cent on BSE in an otherwise weak market after US drug regulator-USFDA classified the company's Unit IV of Hyderabad plant as voluntary action indicated (VAI).

Larsen & Toubro Limited’s construction arm has bagged orders from prestigious clients for its varied businesses. The estimated cost of these orders is worth Rs 1,000-2,500 crore.

The market opened in the red on April 21, 2020. The previous trading session witnessed the Sensex going up by 59.28 points to end at 31,648 and the Nifty was down 5 points to close at 9,261.

The market opened in the red on April 21, 2020. The previous trading session witnessed the Sensex going up by 59.28 points to end at 31,648 and the Nifty was down 5 points to close at 9,261.

lnfibeam Avenues will pay the entire consideration in cash and is likely to complete the acquisition in 30 days. With this, AI Fintech will become a wholly-owned subsidiary of Infibeam Avenues.

The market opened in the red on April 21, 2020, overall volumes in futures & options currently stand at 1,41 crore contracts with a turnover of Rs. 7,46,761.67 crore.

Last week, the company had received a license to manufacture Hydroxychloroquine (HCQ) from State Drug Controller for its Baddi plant in Himachal Pradesh and thereafter, it’s working to commercialise the production of HCQ, in both API as well as in the form of tablets.